http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 15 May 2026 10:28:41 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Leerink+Partners+Starts+Atrium+Therapeutics+%28RNA%29+at+Outperform/26498231.html (Updated - May 15, 2026 10:28 AM EDT) <p>Leerink Partners analyst Joseph Schwartz initiates coverage on Atrium Therapeutics (NASDAQ: RNA) with a Outperform rating and a price target of $25.00.</p><p>The analyst comments "We are initiating coverage of Atrium Therapeutics (RNA) with an Outperform rating and a 12- month PT of $25. We believe Atrium represents an interesting preclinical-stage opportunity in precision cardiology, leveraging Avidity’s clinically validated AOC delivery platform and rare disease development playbook to target genetically-defined cardiomyopathies. While the programs may be higher risk given the lack of human cardiac data to date, we see favorable risk/ reward driven by http://www.streetinsider.com/New+Coverage/Leerink+Partners+Starts+Atrium+Therapeutics+%28RNA%29+at+Outperform/26498231.html Fri, 15 May 2026 10:28:41 -0400 RNA http://www.streetinsider.com/Analyst+Comments/Leerink+Partners+Starts+Atrium+Therapeutics+%28RNA%29+at+Outperform/26498231.html (Updated - May 15, 2026 10:28 AM EDT) <p>Leerink Partners analyst Joseph Schwartz initiates coverage on Atrium Therapeutics (NASDAQ: RNA) with a Outperform rating and a price target of $25.00.</p><p>The analyst comments "We are initiating coverage of Atrium Therapeutics (RNA) with an Outperform rating and a 12- month PT of $25. We believe Atrium represents an interesting preclinical-stage opportunity in precision cardiology, leveraging Avidity’s clinically validated AOC delivery platform and rare disease development playbook to target genetically-defined cardiomyopathies. While the programs may be higher risk given the lack of human cardiac data to date, we see favorable risk/ reward driven by http://www.streetinsider.com/Analyst+Comments/Leerink+Partners+Starts+Atrium+Therapeutics+%28RNA%29+at+Outperform/26498231.html Fri, 15 May 2026 10:28:41 -0400 RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ -- Atrium <span value="ACORN:5020501970" idsrc="xmltag.org" >Therapeutics, Inc.</span> (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the first quarter ended <chron>March 31, 2026</chron>, and highlighted recent corporate progress following its launch as a public company.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atrium+Therapeutics+Reports+First+Quarter+2026+Financial+Results/26495958.html Thu, 14 May 2026 16:40:00 -0400 A.06822034 A.17150087 A.50205019 O.00706867 O.20026344 O.34929518 RNA RNA http://www.streetinsider.com/Corporate+News/Atrium+Therapeutics+receives+%2415+million+milestone+from+Bristol+Myers+Squibb/26354865.html <p>Atrium Therapeutics Inc. (NASDAQ: RNA) received a $15 million development milestone payment from Bristol Myers Squibb Co. (NYSE: BMY) after delivering a development candidate for a cardiology indication under their collaboration agreement.</p><p>The milestone was achieved upon successful delivery of the first licensed compound targeting a cardiology indication under the companies' ongoing partnership. The collaboration focuses on discovering, developing and commercializing RNA-based therapies for cardiovascular indications.</p><p>"This milestone marks a meaningful step forward for Atrium, further expanding our RNA delivery platform and our ability to generate high quality cardiology development candidates," said Kathleen Gallagher, president and chief executive officer of Atrium Therapeutics.</p><p>Under http://www.streetinsider.com/Corporate+News/Atrium+Therapeutics+receives+%2415+million+milestone+from+Bristol+Myers+Squibb/26354865.html Thu, 23 Apr 2026 08:01:01 -0400 BMY RNA http://www.streetinsider.com/Corporate+News/Atrium+Therapeutics+receives+%2415+million+milestone+from+Bristol+Myers+Squibb/26354865.html <p>Atrium Therapeutics Inc. (NASDAQ: RNA) received a $15 million development milestone payment from Bristol Myers Squibb Co. (NYSE: BMY) after delivering a development candidate for a cardiology indication under their collaboration agreement.</p><p>The milestone was achieved upon successful delivery of the first licensed compound targeting a cardiology indication under the companies' ongoing partnership. The collaboration focuses on discovering, developing and commercializing RNA-based therapies for cardiovascular indications.</p><p>"This milestone marks a meaningful step forward for Atrium, further expanding our RNA delivery platform and our ability to generate high quality cardiology development candidates," said Kathleen Gallagher, president and chief executive officer of Atrium Therapeutics.</p><p>Under http://www.streetinsider.com/Corporate+News/Atrium+Therapeutics+receives+%2415+million+milestone+from+Bristol+Myers+Squibb/26354865.html Thu, 23 Apr 2026 08:01:01 -0400 BMY RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Earns+%2415+Million+Milestone+Payment+from+Bristol+Myers+Squibb+Under+Global+Cardiovascular+Collaboration/26354826.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>April 23, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a <money>$15 million</money> development milestone payment from <span value="NYSE:BMY" idsrc="xmltag.org" >Bristol Myers Squibb</span> (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Earns+%2415+Million+Milestone+Payment+from+Bristol+Myers+Squibb+Under+Global+Cardiovascular+Collaboration/26354826.html Thu, 23 Apr 2026 08:00:00 -0400 A.50205019 BMY O.00000283 O.00706867 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Earns+%2415+Million+Milestone+Payment+from+Bristol+Myers+Squibb+Under+Global+Cardiovascular+Collaboration/26354826.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>April 23, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a <money>$15 million</money> development milestone payment from <span value="NYSE:BMY" idsrc="xmltag.org" >Bristol Myers Squibb</span> (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Earns+%2415+Million+Milestone+Payment+from+Bristol+Myers+Squibb+Under+Global+Cardiovascular+Collaboration/26354826.html Thu, 23 Apr 2026 08:00:00 -0400 A.50205019 BMY O.00000283 O.00706867 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Earns+%2415+Million+Milestone+Payment+from+Bristol+Myers+Squibb+Under+Global+Cardiovascular+Collaboration/26354826.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>April 23, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a <money>$15 million</money> development milestone payment from <span value="NYSE:BMY" idsrc="xmltag.org" >Bristol Myers Squibb</span> (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Earns+%2415+Million+Milestone+Payment+from+Bristol+Myers+Squibb+Under+Global+Cardiovascular+Collaboration/26354826.html Thu, 23 Apr 2026 08:00:00 -0400 A.50205019 BMY O.00000283 O.00706867 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Earns+%2415+Million+Milestone+Payment+from+Bristol+Myers+Squibb+Under+Global+Cardiovascular+Collaboration/26354826.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>April 23, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a <money>$15 million</money> development milestone payment from <span value="NYSE:BMY" idsrc="xmltag.org" >Bristol Myers Squibb</span> (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Earns+%2415+Million+Milestone+Payment+from+Bristol+Myers+Squibb+Under+Global+Cardiovascular+Collaboration/26354826.html Thu, 23 Apr 2026 08:00:00 -0400 A.50205019 BMY O.00000283 O.00706867 RNA RNA http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Earns+%2415+Million+Milestone+Payment+from+Bristol+Myers+Squibb+Under+Global+Cardiovascular+Collaboration/26354826.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>April 23, 2026</chron></span> /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a <money>$15 million</money> development milestone payment from <span value="NYSE:BMY" idsrc="xmltag.org" >Bristol Myers Squibb</span> (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atrium+Therapeutics+Earns+%2415+Million+Milestone+Payment+from+Bristol+Myers+Squibb+Under+Global+Cardiovascular+Collaboration/26354826.html Thu, 23 Apr 2026 08:00:00 -0400 A.50205019 BMY O.00000283 O.00706867 RNA RNA